What's Happening?
Sanofi has reported a 26.2% increase in sales for its anti-inflammatory drug Dupixent, reaching €4.2 billion in Q3 2025. This growth comes despite a decline in vaccine sales, which fell by 7.8% to €3.4 billion due to lower influenza vaccination rates
in the US. Sanofi's CEO Paul Hudson highlighted competitive pricing pressures and reduced immunization rates as factors affecting vaccine sales.
Why It's Important?
Dupixent's strong sales performance is crucial for Sanofi as it offsets the decline in vaccine sales. The drug is expected to remain a major revenue stream, with patent protection until 2031. Sanofi's ability to navigate pricing pressures and regulatory changes in the vaccine sector will be key to maintaining its market position. The company's strategic focus on research and development, including the acquisition of Vigil Neuroscience, indicates its commitment to diversifying its product portfolio.
